Neuralink's valuation hinges on clinical trial progress and regulatory milestones for its brain-computer interface technology, with the company remaining pre-revenue and reliant on venture funding rounds to establish market-implied valuations. Recent human implantation data and device performance metrics have shaped trader views on commercial viability in medical applications, while competitive positioning against other neurotech firms and broader risk appetite in private markets influence pricing. Key catalysts include potential FDA updates or new capital raises that could alter implied probabilities of hitting specific thresholds by October 31, 2026, though inherent uncertainty persists given the early-stage nature of the technology and lack of established revenue streams.